{"disease":{"id":"metastatic-high-risk-castration-sensitive-prostate-cancer-cspc","name":"metastatic high risk castration sensitive prostate cancer cspc"},"drugs":{"marketed":[{"drug_id":"chembl-chembl254328","indication_name":"Metastatic high-risk castration-sensitive prostate cancer (CSPC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Abiraterone Acetate","generic_name":"ABIRATERONE","company_name":"Janssen Biotech","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":42,"revenue":null,"mechanism":"Abiraterone Acetate blocks the production of androgens, which are hormones that prostate cancer cells need to grow."}],"pipeline":[],"offLabel":[],"totalMarketed":1,"totalPipeline":0},"trials":{"data":[],"total":0},"guidelines":[],"source":"Drug Landscape verified database"}